Tempus AI (NASDAQ:TEM) EVP Andrew Polovin Sells 8,703 Shares

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 8,703 shares of the stock in a transaction dated Tuesday, May 19th. The stock was sold at an average price of $44.07, for a total transaction of $383,541.21. Following the transaction, the executive vice president directly owned 128,215 shares in the company, valued at $5,650,435.05. The trade was a 6.36% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Andrew Polovin also recently made the following trade(s):

• On Friday, February 20th, Andrew Polovin sold 10,949 shares of Tempus AI stock. The stock was sold at an average price of $60.31, for a total transaction of $660,334.19.

Tempus AI Stock Performance

Shares of TEM stock opened at $46.49 on Friday. The company has a debt-to-equity ratio of 2.96, a quick ratio of 3.15 and a current ratio of 3.31. Tempus AI, Inc. has a one year low of $41.73 and a one year high of $104.32. The company’s 50-day simple moving average is $49.02 and its 200-day simple moving average is $59.39. The stock has a market capitalization of $8.35 billion, a price-to-earnings ratio of -27.03 and a beta of 3.99.

Tempus AI (NASDAQ:TEM) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.08. Tempus AI had a negative net margin of 22.20% and a negative return on equity of 53.83%. The business had revenue of $348.12 million for the quarter, compared to analysts’ expectations of $345.44 million. During the same quarter last year, the company posted ($0.24) earnings per share. The company’s quarterly revenue was up 36.1% compared to the same quarter last year. Equities analysts anticipate that Tempus AI, Inc. will post -1.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Tempus AI

Several institutional investors and hedge funds have recently bought and sold shares of TEM. JPL Wealth Management LLC acquired a new stake in Tempus AI during the third quarter worth about $26,000. Los Angeles Capital Management LLC acquired a new stake in Tempus AI during the fourth quarter worth about $27,000. Harvest Fund Management Co. Ltd acquired a new stake in Tempus AI during the third quarter worth about $38,000. Whittier Trust Co. raised its stake in Tempus AI by 190.0% during the first quarter. Whittier Trust Co. now owns 870 shares of the company’s stock worth $41,000 after acquiring an additional 570 shares during the period. Finally, Lodestone Wealth Management LLC acquired a new stake in shares of Tempus AI in the fourth quarter valued at approximately $42,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on TEM. Mizuho began coverage on shares of Tempus AI in a research report on Thursday, February 19th. They set an “outperform” rating and a $100.00 price target on the stock. Morgan Stanley reduced their price target on shares of Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a research report on Tuesday, March 3rd. TD Cowen increased their price target on shares of Tempus AI from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. HC Wainwright dropped their price objective on shares of Tempus AI from $95.00 to $64.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Tempus AI from $80.00 to $60.00 and set a “neutral” rating on the stock in a research note on Wednesday, February 25th. Nine research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $68.64.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.